NCT07140900
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07140900
Title Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Amgen
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | CHE | AUS

Facility Status City State Zip Country Details
Dana Farber Cancer Institute RECRUITING Boston Massachusetts 02215 United States Details
University of Minnesota RECRUITING Minneapolis Minnesota 55455 United States Details
Chris OBrien Lifehouse RECRUITING Camperdown New South Wales 2050 Australia Details
Calvary Mater Newcastle Hospital RECRUITING Waratah New South Wales 2298 Australia Details
Cabrini Hospital RECRUITING Clayton Victoria 3168 Australia Details
Peter MacCallum Cancer Centre RECRUITING Melbourne Victoria 3000 Australia Details
The Alfred Hospital RECRUITING Melbourne Victoria 3004 Australia Details
Kantonsspital Graubuenden RECRUITING Chur 7000 Switzerland Details
Centre Hospitalier Universitaire Vaudois RECRUITING Lausanne 1011 Switzerland Details
Kantonsspital Sankt Gallen RECRUITING Sankt Gallen 9007 Switzerland Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field